SPY002 not checked

Spyre Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Ulcerative Colitis (2 trials), Inflammatory Bowel Diseases (2 trials), Colitis (2 trials), Colitis, Ulcerative (2 trials)
Main trialPhase 2
“This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.”In the company’s words, NCT07012395 on ClinicalTrials.gov

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jun 2027 A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Phase 2Enrolling by invitation 2 Mar 2029 Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Phase 1Completed 19 Aug 2026 A Study of SPY002-091 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SPY002

Following is part of Solo: you see every change to SPY002 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in